These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 34491888)

  • 1. Analysis of the adverse events following immunization with inactivated quadrivalent influenza vaccine from 2018 to 2020 in Zhejiang province, with a comparison to trivalent influenza vaccine.
    Lv H; Pan X; Liang H; Wang Y; Hu Y
    Hum Vaccin Immunother; 2021 Nov; 17(11):4617-4622. PubMed ID: 34491888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine using the national adverse event following immunization surveillance system from Zhejiang province, 2018-2020.
    Hu Y; Pan X; Shen L; Chen F; Wang Y; Liang H; Chen Y; Lv H
    Hum Vaccin Immunother; 2021 Dec; 17(12):5447-5453. PubMed ID: 34613883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China.
    Pan X; Lv H; Liang H; Wang Y; Shen L; Chen F; Chen Y; Hu Y
    Hum Vaccin Immunother; 2022 Dec; 18(1):2021711. PubMed ID: 35108152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active SMS-based influenza vaccine safety surveillance in Australian children.
    Pillsbury A; Quinn H; Cashman P; Leeb A; Macartney K;
    Vaccine; 2017 Dec; 35(51):7101-7106. PubMed ID: 29128379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China.
    Hu Y; Pan X; Chen F; Wang Y; Liang H; Shen L; Chen Y; Lv H
    Hum Vaccin Immunother; 2022 Dec; 18(1):2035141. PubMed ID: 35240930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
    Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M
    Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: A phase III randomized study.
    Vesikari T; Nauta J; Lapini G; Montomoli E; van de Witte S
    Int J Infect Dis; 2020 Mar; 92():29-37. PubMed ID: 31838217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western Australia.
    Regan AK; Tracey L; Gibbs R
    Vaccine; 2015 Nov; 33(46):6149-51. PubMed ID: 26476362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
    Kieninger D; Sheldon E; Lin WY; Yu CJ; Bayas JM; Gabor JJ; Esen M; Fernandez Roure JL; Narejos Perez S; Alvarez Sanchez C; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
    BMC Infect Dis; 2013 Jul; 13():343. PubMed ID: 23883186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S; Nauta J; Montomoli E; Weckx J
    Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comparison with Adverse Events Following Immunization Associated with Sabin-Strains and Salk-Strains Inactivated Polio Vaccines in Zhejiang Province, China.
    Lv H; Pan X; Liang H; Chen Y; Wang Y; Chen F; Shen L; Hu Y
    Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials.
    Moa AM; Chughtai AA; Muscatello DJ; Turner RM; MacIntyre CR
    Vaccine; 2016 Jul; 34(35):4092-4102. PubMed ID: 27381642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents.
    Huang C; Fu X; Zhou Y; Mi F; Tian G; Liu X; Wu J; Ding C; Yan D; Li L; Yang S
    Vaccine; 2020 Feb; 38(6):1332-1344. PubMed ID: 31948819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world safety profile of the 9-valent human papillomavirus vaccine: A study in Zhejiang, China from 2019 to 2021.
    Chen F; Pan X; Liang H; Shen L; Wang Y; Chen Y; Lv H; Hu Y
    Hum Vaccin Immunother; 2022 Dec; 18(7):2152256. PubMed ID: 36484114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children.
    Langley JM; Carmona Martinez A; Chatterjee A; Halperin SA; McNeil S; Reisinger KS; Aggarwal N; Huang LM; Peng CT; Garcia-Sicilia J; Salamanca de la Cueva I; Cabañas F; Treviño-Garza C; Rodríguez-Weber MA; de la O M; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK
    J Infect Dis; 2013 Aug; 208(4):544-53. PubMed ID: 23847058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system.
    Pan X; Lv H; Chen F; Wang Y; Liang H; Shen L; Chen Y; Hu Y
    Hum Vaccin Immunother; 2021 Oct; 17(10):3823-3830. PubMed ID: 34170800
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in China.
    Hu Y; Shao M; Hu Y; Liang Q; Jia N; Chu K; Xu L; Li J; Li C; Zhu F
    Hum Vaccin Immunother; 2020 Jul; 16(7):1691-1698. PubMed ID: 32347785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.
    Domachowske JB; Pankow-Culot H; Bautista M; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
    J Infect Dis; 2013 Jun; 207(12):1878-87. PubMed ID: 23470848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
    Greenberg DP; Robertson CA; Noss MJ; Blatter MM; Biedenbender R; Decker MD
    Vaccine; 2013 Jan; 31(5):770-6. PubMed ID: 23228813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.